Maryland's Protein-based COVID-19 Vaccine Ships to Europe
Maryland-based Novavax, Inc. recently announced the first doses of Nuvaxovid™ COVID-19 Vaccine have begun shipping to European Union member states. Nuvaxovid is the first protein-based COVID-19 vaccine authorized for use in Europe. The first wave of Nuvaxovid vaccine shipments on Feb. 23, 2022, included Germany, France, and Austria.
Source: precisionvaccinations.com